|
HY-P1240B-1mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (acetate)
|
|
COVID-19-immunoregulation
|
|
|
HY-P1240B-10mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (acetate)
|
|
COVID-19-immunoregulation
|
|
|
HY-P1240B-5mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (acetate)
|
|
COVID-19-immunoregulation
|
|
|
HY-P1240A-1mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (TFA)
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P1240A-10mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (TFA)
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P1240A-5mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (TFA)
|
|
Neuroscience-Neuromodulation
|
|
|
HY-112616-10mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-100mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-25mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-5mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-50mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-P99376-1mg
|
MedChemexpress LLC
|
Narsoplimab [CAS 2108782-45-0]
|
|
COVID-19-anti-virus
|
|
|
HY-P99376-10mg
|
MedChemexpress LLC
|
Narsoplimab [CAS 2108782-45-0]
|
|
COVID-19-anti-virus
|
|
|
HY-P99376-5mg
|
MedChemexpress LLC
|
Narsoplimab [CAS 2108782-45-0]
|
|
COVID-19-anti-virus
|
|
|
HY-P99379-1mg
|
MedChemexpress LLC
|
Nidanilimab [CAS 2171061-85-9]
|
|
Cancer-programmed cell death
|
|
|
HY-P99379-10mg
|
MedChemexpress LLC
|
Nidanilimab [CAS 2171061-85-9]
|
|
Cancer-programmed cell death
|
|
|
HY-P99379-5mg
|
MedChemexpress LLC
|
Nidanilimab [CAS 2171061-85-9]
|
|
Cancer-programmed cell death
|
|
|
HY-P9968-1mg
|
MedChemexpress LLC
|
Nimotuzumab [CAS 780758-10-3]
|
|
Cancer-Kinase/protease
|
|
|
HY-P9968-5mg
|
MedChemexpress LLC
|
Nimotuzumab [CAS 780758-10-3]
|
|
Cancer-Kinase/protease
|
|
|
HY-P9932-1mg
|
MedChemexpress LLC
|
Obiltoxaximab [CAS 1351337-07-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P9932-10mg
|
MedChemexpress LLC
|
Obiltoxaximab [CAS 1351337-07-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P9932-5mg
|
MedChemexpress LLC
|
Obiltoxaximab [CAS 1351337-07-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99308-1mg
|
MedChemexpress LLC
|
Ocaratuzumab [CAS 1169956-08-4]
|
|
Cancer-programmed cell death
|
|
|
HY-P99308-10mg
|
MedChemexpress LLC
|
Ocaratuzumab [CAS 1169956-08-4]
|
|
Cancer-programmed cell death
|
|
|
HY-P99308-5mg
|
MedChemexpress LLC
|
Ocaratuzumab [CAS 1169956-08-4]
|
|
Cancer-programmed cell death
|
|
